Biologic Therapies in Oral Mucous Membrane Pemphigoid: An Update

Background: Mucous membrane pemphigoid (MMP) is a rare chronic autoimmune subepithelial blistering disease characterized by predominant oral mucosal involvement and a risk of irreversible scarring affecting multiple mucosal sites. Although conventional immunosuppressive therapy remains the cornerstone of treatment, refractory disease, relapses, and treatment-related toxicity have prompted increasing interest in biologic therapies. This review summarizes the current evidence regarding biologic agents for MMP, with particular focus on patients with oral involvement. Methods: A narrative review of the available literature was conducted, including retrospective studies, case series, and case reports evaluating biologic therapies in MMP. Evidence regarding rituximab, Janus kinase (JAK) inhibitors, anti-tumor necrosis factor-α (TNF-α) agents, dupilumab and omalizumab was critically reviewed. Results: Rituximab is supported by the strongest clinical evidence, consistently achieving high rates of disease control and complete remission in severe or refractory MMP. Emerging evidence indicates that JAK inhibitors may represent a promising targeted therapeutic option, with rapid and sustained clinical responses reported in both retrospective studies and individual cases. Anti-TNF-α agents, particularly etanercept, have demonstrated favorable outcomes in isolated reports, whereas evidence for adalimumab remains limited. Dupilumab and omalizumab have shown encouraging preliminary results, although current evidence is restricted to a few patients. Conclusions: Biologic therapies are expanding the therapeutic options for refractory oral MMP. Rituximab currently represents the best-supported biologic treatment, with evidence from relatively large retrospective cohorts, whereas JAK inhibitors appear particularly promising, despite the limited data available from small case series and case reports. Evidence supporting other biologic agents remains even more limited, highlighting the need for prospective multicenter studies to establish their long-term efficacy, safety, and optimal positioning in the management of MMP.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-18
DOI
https://doi.org/10.3390/jcm15229054
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biologic Therapies in Oral Mucous Membrane Pemphigoid: An Update

Stefania Leuci, Vera Panzarella, Gianrico Spagnuolo, Michele Davide Mignogna et al.
1 links
Journal of Clinical Medicine
Autoimmune Bullous Skin Diseases
article

Biologic Therapies in Oral Mucous Membrane Pemphigoid: An Update

Stefania Leuci, Vera Panzarella, Gianrico Spagnuolo, Michele Davide Mignogna, Simone Liguori, Maria Elena Mauceri, Sabrina Capasso
article en

Abstract

Background: Mucous membrane pemphigoid (MMP) is a rare chronic autoimmune subepithelial blistering disease characterized by predominant oral mucosal involvement and a risk of irreversible scarring affecting multiple mucosal sites. Although conventional immunosuppressive therapy remains the cornerstone of treatment, refractory disease, relapses, and treatment-related toxicity have prompted increasing interest in biologic therapies. This review summarizes the current evidence regarding biologic agents for MMP, with particular focus on patients with oral involvement. Methods: A narrative review of the available literature was conducted, including retrospective studies, case series, and case reports evaluating biologic therapies in MMP. Evidence regarding rituximab, Janus kinase (JAK) inhibitors, anti-tumor necrosis factor-α (TNF-α) agents, dupilumab and omalizumab was critically reviewed. Results: Rituximab is supported by the strongest clinical evidence, consistently achieving high rates of disease control and complete remission in severe or refractory MMP. Emerging evidence indicates that JAK inhibitors may represent a promising targeted therapeutic option, with rapid and sustained clinical responses reported in both retrospective studies and individual cases. Anti-TNF-α agents, particularly etanercept, have demonstrated favorable outcomes in isolated reports, whereas evidence for adalimumab remains limited. Dupilumab and omalizumab have shown encouraging preliminary results, although current evidence is restricted to a few patients. Conclusions: Biologic therapies are expanding the therapeutic options for refractory oral MMP. Rituximab currently represents the best-supported biologic treatment, with evidence from relatively large retrospective cohorts, whereas JAK inhibitors appear particularly promising, despite the limited data available from small case series and case reports. Evidence supporting other biologic agents remains even more limited, highlighting the need for prospective multicenter studies to establish their long-term efficacy, safety, and optimal positioning in the management of MMP.

Journal of Clinical MedicineVol. 15(22)
Dr. D.Y. Patil Vidyapeeth, Pune (IN), Dr D Y Patil Dental College & Hospital (IN), University of Naples Federico II (IT), University of Palermo (IT)
Good health and well-being
Autoimmune Bullous Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon